论文信息 - Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis.

Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis.

The effects of haemodialysis on the pharmacokinetics of a carbapenem, biapenem, were evaluated in five patients with end-stage renal disease, who received 1 h iv infusions of 300 mg biapenem on both the days on and off 4 h haemodialysis. With haemodialysis, plasma biapenem exhibited two elimination phases, one during and the other after haemodialysis with half-lives of 1.16 +/- 0.12 and 3.33 +/- 0. 91 h, respectively. Ninety percent of biapenem was removed from blood to dialysate. Without haemodialysis, plasma biapenem was mono-exponentially eliminated with a half-life of 4.35 +/- 1.30 h.

[1] E. Lee,et al. Pharmacokinetics of Intravenous Vancomycin in Patients with End‐Stage Renal Failure , 1990, Therapeutic drug monitoring.

[2] G. Alván,et al. Adverse Effects of Monobactams and Carbapenems , 1995, Drug safety.

[3] D. Höffler,et al. Biapenem pharmacokinetics in healthy volunteers and in patients with impaired renal function. , 1997, Arzneimittel-Forschung.

[4] O. Kozawa,et al. Pharmacokinetics and Safety of a New Parenteral Carbapenem Antibiotic, Biapenem (L-627), in Elderly Subjects , 1998, Antimicrobial Agents and Chemotherapy.

[5] C. Marone,et al. Clearance of ceftriaxone during haemodialysis using cuprophane, haemophane and polysulfone dialysers , 1997, European Journal of Clinical Pharmacology.

[6] S. Mitsuhashi,et al. In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I , 1990, Antimicrobial Agents and Chemotherapy.

[7] M. Nakashima,et al. Phase 1 study of L-627, biapenem, a new parenteral carbapenem antibiotic. , 1993, International journal of clinical pharmacology, therapy, and toxicology.